Adial Pharmaceuticals Reports $2M Net Loss, Enters Collaboration with Molteni Farmaceutici

Adial Pharmaceuticals, Inc. reported a net loss of approximately $2.0 million for the three months ended March 31, 2026, a decrease from a net loss of $2.2 million during the same period in 2025. The company's total operating expenses for the first quarter of 2026 were approximately $2.0 million, down from $2.3 million in the prior year, primarily due to a significant reduction in research and development expenses, which fell by 42% to $433,000. General and administrative expenses increased slightly by 3% to $1.6 million, attributed to higher business development costs.

The company's financial position showed a decline in total assets, which decreased to $5.2 million as of March 31, 2026, compared to $6.7 million at the end of 2025. Cash and cash equivalents also fell to $4.6 million from $5.9 million. Current liabilities increased to $1.5 million, up from $1.4 million, with accrued expenses rising significantly to $936,504, primarily due to increased employee compensation obligations. The accumulated deficit grew to approximately $92 million, reflecting ongoing operational losses since inception.

In terms of strategic developments, Adial entered into a collaboration framework agreement with Molteni Farmaceutici on March 3, 2026, aimed at commercializing its lead product candidate, AD04, in Europe. This partnership is expected to include milestone payments and royalties, potentially valued at nearly $60 million, contingent on the successful progression of AD04 through clinical development. The company is also preparing for a Phase 3 clinical trial of AD04, which is anticipated to commence later in 2026, pending adequate funding.

Operationally, Adial's cash flow from operating activities for the first quarter of 2026 was approximately $(1.6 million), a slight increase in cash used compared to $(1.6 million) in the same period of 2025. The company raised approximately $315,000 through the sale of common stock under its at-the-market offering agreement during the quarter. However, the company has indicated that its current cash reserves may not be sufficient to fund operations for the next twelve months, raising concerns about its ability to continue as a going concern without additional capital.

Looking ahead, Adial Pharmaceuticals is actively pursuing additional financing options to support its clinical development plans and operational needs. The company is exploring various avenues, including equity offerings and strategic partnerships, to secure the necessary funds. However, management has acknowledged the uncertainty surrounding these efforts, emphasizing the potential impact on the company's ability to execute its business strategy and continue its research and development programs.